Product Description
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Eculizumab making it ideal for research use. This Eculizumab biosimilar reacts with human terminal complement component 5 (C5). C5 is a precursor protein synthesized in the liver. During complement activation, C5 is cleaved, producing two disulfide linked glycoproteins C5alpha and C5beta. C5alpha is further cleaved by C5 convertase into C5a and C5alpha, the latter binds to C5beta to form C5b, which in turn sequentially recruits C6-C9 to form the membrane attack complex (MAC). MAC destroys pathogens by forming a lytic pore in their membrane. Eculizumab inhibits the cleavage of C5 to C5alpha and C5beta. Eculizumab is used for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
* VAT and shipping costs not included. Errors and price changes excepted
